Role of phospholamban in cyclic GMP mediated signaling in cardiac myocytes

Cellular Physiology and Biochemistry

Volumn 20, Issue 1-4, 2007, Pages 157-166

  Zhang, Qihang ^a   Scholz, Peter M ^a   Pilzak, Anna ^a   Su, Jun ^a   Weiss, Harvey R ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cardiac myocyte function; Cyclic GMP; Natriuretic peptides; Nitric oxide; Phospholamban

Indexed keywords

8 BROMO CYCLIC GMP; CALCIUM; CYCLIC GMP; FURA 2; N ACETYL S NITROSOPENICILLAMINE; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE DONOR; PHOSPHOLAMBAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; HEART MUSCLE CELL; HEART VENTRICLE; MOUSE; MUSCLE FIBER CONTRACTION; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WILD TYPE;

EID: 34250776431     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104163     Document Type: Article

References (31)

1. Shah AM, MacCarthy PA: Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 2000;86:49-86.
2. Zhang Q, Scholz PM, He Y, Tse J, Weiss HR: Cyclic GMP signaling and regulation of SERCA activity during cardiac myocyte contraction. Cell Calcium 2005;37:259-266.
3. Zieman SJ, Gerstenblith G, Lakatta EG, Rosas GO, Vandegaer K, Ricker KM, Hare JM: Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine. Circ Res 2001;88:88-102.
4. 2+ -ATPase in vascular endothelial cells. Life Sci 2003;73:2019-2028.
5. 2+ -ATPase. Pharmacology 2002;64:106-112.
6. Suko J, Maurer-Fogy I, Plank B, Bertel O, Wyskovsky W, Hohenegger M, Hellmann G: Phosphorylation of serine 2843 in ryanodine receptor-calcium release channel of skeletal muscle by cAMP-, cGMP- and CaM-dependent protein kinase. Biochim Biophys Acta 1993;1175:193-206.
7. 2 ACh receptor. Am J Physiol 2001;281:C1251-C1258.
8. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ: Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999;84:1020-1031.
9. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E, Trautwein C, Lohmann SM, Drexler H: Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 2002;39:87-92.
10. Bers DM: Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 2000;87:275-281.
11. 2+ -ATPase modulates cardiac contraction and relaxation. Cardiovasc Res 2003;57:20-207.
12. 2+ release. Circ Res 2003;92:904-11.
13. Simmerman HK, Jones LR: Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 1998;78:921-947.
14. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol Cell Biol 2003;4:566-577.
15. Su J, Scholz PM, Weiss HR: Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med 2005;230:242-250.
16. Birschmann I, Walter U: Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate- dependent protein kinase. Acta Biochim Pol 2004;51: 397-404.
17. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F: Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 2003;93: 907-916.
18. Baxter GH: Natriuretic peptides and myocardial ischaemia. Basic Res Cardiol 2004;99:90-93.
19. Kuhn M: Cardiac and intestinal natriuretic peptides: insights from genetically modified mice. Peptides 2005;26:1078-1085.
20. Nir A, Zhang DF, Fixler R, Burnett JR JC, Eilam Y, Hasin Y: C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol 2001;412:195-201.
21. Pierkes M, Gambaryan S, Boknik P, Lohmann SM, Schmitz W, Potthast R, Holtwick R, Kuhn M: Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice. Cardiovasc Res 2002;53:852-861.
22. 2+ influx. Circ Res 1999;84:210-219.
23. Frank K, Kranias EG: Phospholamban and cardiac contractility. Ann Med 2000;32:572-578.
24. Cornwell TL, Pryzwansky KB, Wyatt TA, Lincoln TM: Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells. Mol Pharmacol 1991;40:923-931.
25. Brusq JM, Mayoux E, Guigui L, Kirilovsky J: Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol 1999;128:206-212.
26. Despa S, Boaauyr J, Han F, Ginsburg KS, Jia LG, Kutchai H, Tucker AL, Bers DM: Phospholemman-phosphorylation mediates the beta-adrenergic effects on Na/K pump function in cardiac myocytes. Circ Res 2005;97:252-269.
27. Hofmann F, Ammendola A, Schlossmann J: Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 2000;113:1671-1676.
28. Koller A, Schlossmann J, Ashman K, Uttenweiler-Joseph S, Ruth P, Hofmann F: Association of phospholamban with a cGMP kinase signaling complex. Biochem Biophys Res Commun 2003;300:155-160.
29. Li L, Chu G, Kranias EG, Bers DM: Factors that control sarcoplasmic reticulum calcium release in intact ventricular myocytes. Ann N Y Acad Sci 1998;853:157-177.
30. Schlossmann J, Ammendola A, Ashman K, Zong X, Huber A, Neubauer G, Wang GX, Allescher HD, Korth M, Wilm M, Hofmann F, Ruth P: Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature 2000;404:197-201.
31. Janczewski AM, Zahid M, Lemster BH, Frye CS, Gibson G, Higuchi Y, Kranias EG, Feldman AM, McTiernan CF: Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Cardiovasc Res 2004; 62:468-480.